The effect of hyperhomocysteinemia on the level of antioxidant enzymes in the blood and on the severity of diabetic neuropathy in patients with type 2 diabetes mellitus

• Alexander S. Ametov
• Anyuta A. Kosyan
• Evgeniya Yu. Pashkova

Abstract

Aim. To assess the effect of hyperhomocysteinemia on the level of antioxidant enzymes in the blood and on the severity of diabetic neuropathy (DN) in patients with type 2 diabetes.

Material and methods. 30 patients with type 2 diabetes and with DN were divided into 2 groups: the 1^st group with hyperhomocysteinemia in the blood (n=14) and the 2^nd group without hyperhomocysteinemia (n=16). There were assessed the state of the peripheral nerves (TSS and NIS-LL scales, electroneuromiography) and indicators of antioxidant enzymes superoxidedismutas (SOD) and glutathionperoxidas (GPO).

Results and discussion. In the 1^st group, the mean level SOD and GPO were lower compared to the 2 ^nd group (p<0.05), the mean scores on the TSS and NIS-LL scales in the 1^st group were higher than in 2^nd (p<0.05). In the 1^st group the level of homocystein in the blood correlated with the level of TSS (rs=0.2) and NIS-LL scales (rs=0.3) (p<0.05), with the amplitude of the sensory response (rs=-0.3) and the nerve conduction velocity (rs=-0.364) (p<0.05) on n. suralis. The homocystein level in the blood was negatively correlated with GPO (rs=-0.4) (p<0.05) and with SOD (rs=-0.4) (p<0.05) in the 1^st group.

Conclusion. Elevated level of homocystein negatively impacts the level of antioxidant enzymes and the severity of DN.

Keywords:hyperhomocysteinemia, antioxidant enzymes, diabetic neuropathy, oxidative stress, type 2 diabetes mellitus

References

1. Tesfaye S., Boulton A.J., Dickenson A.H. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013; 36: 2456-65.

2. Boulton A.J., Kirsner R.S., Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004; 351: 48-55.

3. Singh N., Armstrong D.G., Lipsky B.A. Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293: 217-28.

4. Gore M., Brandenburg N.A., Dukes E., Hoffman D.L., et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005; 30: 374-85.

5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54: 1615-25.

6. Bogdanov E.I., Talantov V.V., Mukhamedzyanov R.Z. Diabetic neuropathy. Vestnik nevrologii [Bulletin of Neurology]. 2000; (3/4): 59-67. (in Russian)

7. Obeid R., Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006; 580 (13): 2994-3005.

8. Wang H., Cui K., Xu K., Xu S. Association between plasma homocysteine and progression of early nephropathy in type 2 diabetic patients. Int J Clin Exp Med. 2015; 8 (7): 11 174-80.

9. Li J., Shi M., Zhang H., Yan L., et al. Relation of homocysteine to early nephropathy in patients with type 2 diabetes. Clin Nephrol. 2012; 77 (4): 305-10.

10. Brazionis L., Rowley K., Itsiopoulos C., Harper C.A., O’Dea K. Homocysteine and diabetic retinopathy. Diabetes Care. 2008; 31 (1): 50-6.

11. Rudy A., Kowalska I., Str^czkowski M., Kinalska I. Homocysteine concentrations and vascular complications in patients with type 2 diabetes. Diabetes Metab. 2005; 31 (2): 112-7.

12. Jacobsen D.W. Hyperhomocysteinemia and oxidative stress. Arterioscler Thromb Vasc Biol. 2000; 20: 1182-4.

13. Ametov A.S., Kosyan A.A. The role of homocysteine in the development of diabetic polyneuropathy and endothelial dysfunction. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2019; 8 (1): 32-9. (in Russian)

14. Weiss N., Zhang Y.Y., Heydrick S., Bierl C., et al. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci USA. 2001; 98 (22): 12 503-8.

15. Ametov A.S., Kamynina L.L., Rozhdestvenskaya O.A., Pashko-va E.Yu. The positive metabolic and antioxidative properties of the testosterone replacement therapy at the combination of the type 2 diabetes mellitus and the hypogonadism. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2016; (3): 83-93. (in Russian)

16. Hoogeveen E.K., Kostense P.J., Jakobs C., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation. 2000; 101: 1506-11.

17. Stanger O., Herrmann W., Pietrzik K., et al. Consensus paperon the rational clinical use of homocysteine, folic acid and B-vitamins incardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003; 41: 1392-403.

18. Pop-Busui R., Sima A., Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev. 2006; 22 (4): 257-73.

19. Wile D.J., Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010; 33 (1): 156-61.

20. Roy R.P., Ghosh K., Ghosh M., Acharyya A., et al. Study of Vitamin B 12 deficiency and peripheral neuropathy in metformin-treated early type 2 diabetes mellitus. Indian J Endocrinol Metab. 2016; 20: 631-7.

21. Nardin R.A., Amic A.N., Raynor E.M. Vitamin B(12) and methylmalonic acid levels in patients presenting with polyneuropathy. Muscle Nerve. 2007; 36 (4): 532-5.

22. Markle H.V. Cobalamin. Crit Rev Clin Lab Sci. 1996; 33: 247-356.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)